Sign In
Buy DRIO
$7.50
-0.1000 (-1.32%)
At Close: Jun 05, 2026
Findings reinforce that engagement data provide clinical signals directly impacting ROI Analysis further reveals specific frequency of measurements that drive clinical outcomes and bend the cost curve
As oral GLP-1s enter the market with slightly more modest weight and glycemic outcomes than injectable formulations, Dario integrates structured behavioral reinforcement to optimize real-world success
Dario Surpasses 100 Scientific Studies, Cementing Leadership Among Digital Health's Most Evidence-Based Platforms
08:00am, Wednesday, 21'st Jan 2026
Growing body of peer-reviewed publications and rigorously reviewed conference research reinforces Dario's position as trusted partner for organizations seeking to reduce cost, improve outcomes and sim
Contrasting DarioHealth (NASDAQ:DRIO) and CardioGenics (OTCMKTS:CGNH)
05:08am, Saturday, 27'th Dec 2025
CardioGenics (OTCMKTS:CGNH - Get Free Report) and DarioHealth (NASDAQ: DRIO - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on t
Dario Launches DarioIQ™ AI Integration in Dario Health App with Direct-to-Consumer First Version for Hypertension Members
08:00am, Wednesday, 10'th Dec 2025
First in-market activation of Dario's GenAI roadmap lays clinical and technical foundation for a seamless, conversational AI experience across the entire Dario platform DarioIQ™ reflects years of i
Peer-reviewed JMIR Cardio study demonstrates real-world clinical impact of data-driven digital nudges on hypertension outcomes Data-driven engagement translates to lower health risks and downstream co
DarioHealth Far Exceeds 2025 New Client Target with 79 New Accounts Signed Year-to-Date
08:00am, Tuesday, 02'nd Dec 2025
34 new employer clients added in the past two weeks expected to contribute to H1 2026 revenue Data-driven outcomes drive employer adoption, highlighting Dario's market leadership as partner of choice,
Sanofi and Symphony Health teams conducted the study demonstrating how Dario's digital, diabetes intervention platform reduces real-world healthcare burden and cost compared to usual care Representing
DarioHealth Corp. (DRIO) Q3 2025 Earnings Call Transcript
03:11pm, Thursday, 13'th Nov 2025
DarioHealth Corp. ( DRIO ) Q3 2025 Earnings Call November 13, 2025 8:30 AM EST Company Participants Zoe Harrison Erez Raphael - CEO & Director Steven Nelson - President & Chief Commercial Officer Chen
DarioHealth Corp. (DRIO) Reports Q3 Loss, Lags Revenue Estimates
08:45am, Thursday, 13'th Nov 2025
DarioHealth Corp. (DRIO) came out with a quarterly loss of $1.85 per share versus the Zacks Consensus Estimate of a loss of $2.63. This compares to a loss of $2.6 per share a year ago.
DarioHealth Reports Third Quarter 2025 Financial and Operating Results
06:30am, Thursday, 13'th Nov 2025
Third quarter 2025 revenue was $5.0 million, compared to $7.4 million in the third quarter of 2024, and $5.4 million in the second quarter of 2025 Targeting $12.4 million in new business, reflecting b
Analysis based on claims data highlights significant cost savings, especially among high-risk members NEW YORK , Nov. 12, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHe
DarioHealth to Report Third Quarter 2025 Results on Thursday, November 13, 2025
08:30am, Thursday, 06'th Nov 2025
Company to host conference call and webcast at 8:30 a.m. Eastern Time NEW YORK , Nov. 6, 2025 /PRNewswire/ --DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of DarioHealth Corp. (NASDAQ: DRIO)
10:32am, Wednesday, 29'th Oct 2025
NEW YORK , Oct. 29, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating DarioHealth Corp. (NASDAQ: DRIO) on behalf of the company's shareholders. The investigation seeks
Wall Street Analysts Predict a 42.77% Upside in DarioHealth (DRIO): Here's What You Should Know
10:56am, Tuesday, 14'th Oct 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 42.8% in DarioHealth (DRIO). While the effectiveness of this highly sought-after metric is questionable, the po
